Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03375320 · FLOW

Participant flow

Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors · Source last updated 2026-08-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.\> \> Cabozantinib S-malate: Given PO\> \> Computed Tomography: Undergo CT\> \> Magnetic Resonance Imaging: Undergo MRI\> \> Quality-of-Life Assessment: Ancillary studies\> \> X-Ray Imaging: Undergo x-ray
    id
    FG000
    title
    Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET])
  2. description
    Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.\> \> Computed Tomography: Undergo CT\> \> Magnetic Resonance Imaging: Undergo MRI\> \> Placebo Administration: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> X-Ray Imaging: Undergo x-ray
    id
    FG001
    title
    Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET])
  3. description
    Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.\> \> Cabozantinib S-malate: Given PO\> \> Computed Tomography: Undergo CT\> \> Magnetic Resonance Imaging: Undergo MRI\> \> Quality-of-Life Assessment: Ancillary studies\> \> X-Ray Imaging: Undergo x-ray
    id
    FG002
    title
    Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET])
  4. description
    Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.\> \> Computed Tomography: Undergo CT\> \> Magnetic Resonance Imaging: Undergo MRI\> \> Placebo Administration: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> X-Ray Imaging: Undergo x-ray
    id
    FG003
    title
    Arm IIb (Placebo, Pancreatic NET Cohort [pNET])
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        34
      2. group Id
        FG001
        num Subjects
        9
      3. group Id
        FG002
        num Subjects
        10
      4. group Id
        FG003
        num Subjects
        0
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        5
      4. group Id
        FG003
        num Subjects
        4
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        55
      2. group Id
        FG001
        num Subjects
        41
      3. group Id
        FG002
        num Subjects
        29
      4. group Id
        FG003
        num Subjects
        24
      type
      Progressive disease
    5. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      Alternative treatment
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        0
      type
      Other disease
    7. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      Withdrawal prior to initiation
    8. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        1
      type
      Physician Decision
    9. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Non-compliance
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        134
      2. group Id
        FG001
        num Subjects
        69
      3. group Id
        FG002
        num Subjects
        64
      4. group Id
        FG003
        num Subjects
        31
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        132
      2. group Id
        FG001
        num Subjects
        67
      3. group Id
        FG002
        num Subjects
        63
      4. group Id
        FG003
        num Subjects
        31
      type
      Initiated Treatment
    3. achievements
      1. group Id
        FG000
        num Subjects
        21
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        14
      4. group Id
        FG003
        num Subjects
        2
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        113
      2. group Id
        FG001
        num Subjects
        62
      3. group Id
        FG002
        num Subjects
        50
      4. group Id
        FG003
        num Subjects
        29
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.\> \> Cabozantinib S-malate: Given PO\> \> Computed Tomography: Undergo CT\> \> Magnetic Resonance Imaging: Undergo MRI\> \> Quality-of-Life Assessment: Ancillary studies\> \> X-Ray Imaging: Undergo x-ray
    id
    FG000
    title
    Arm Ia (Cabozantinib S-malate, Extra-pancreatic NET Cohort [epNET])
  2. description
    Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.\> \> Computed Tomography: Undergo CT\> \> Magnetic Resonance Imaging: Undergo MRI\> \> Placebo Administration: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> X-Ray Imaging: Undergo x-ray
    id
    FG001
    title
    Arm IIa (Placebo, Extra-pancreatic NET Cohort [epNET])
  3. description
    Patients receive cabozantinib S-malate PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study.\> \> Cabozantinib S-malate: Given PO\> \> Computed Tomography: Undergo CT\> \> Magnetic Resonance Imaging: Undergo MRI\> \> Quality-of-Life Assessment: Ancillary studies\> \> X-Ray Imaging: Undergo x-ray
    id
    FG002
    title
    Arm Ib (Cabozantinib S-malate, Pancreatic NET Cohort [pNET])
  4. description
    Patients receive placebo PO QD on days 1-28 of each cycle. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo CT, MRI, and/or x-ray imaging during screening and on study. Patients may crossover to receive cabozantinib S-malate at the time of disease progression.\> \> Computed Tomography: Undergo CT\> \> Magnetic Resonance Imaging: Undergo MRI\> \> Placebo Administration: Given PO\> \> Quality-of-Life Assessment: Ancillary studies\> \> X-Ray Imaging: Undergo x-ray
    id
    FG003
    title
    Arm IIb (Placebo, Pancreatic NET Cohort [pNET])
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        34
      2. group Id
        FG001
        num Subjects
        9
      3. group Id
        FG002
        num Subjects
        10
      4. group Id
        FG003
        num Subjects
        0
      type
      Adverse Event
    2. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        3
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Death
    3. reasons
      1. group Id
        FG000
        num Subjects
        7
      2. group Id
        FG001
        num Subjects
        4
      3. group Id
        FG002
        num Subjects
        5
      4. group Id
        FG003
        num Subjects
        4
      type
      Withdrawal by Subject
    4. reasons
      1. group Id
        FG000
        num Subjects
        55
      2. group Id
        FG001
        num Subjects
        41
      3. group Id
        FG002
        num Subjects
        29
      4. group Id
        FG003
        num Subjects
        24
      type
      Progressive disease
    5. reasons
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      Alternative treatment
    6. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        3
      4. group Id
        FG003
        num Subjects
        0
      type
      Other disease
    7. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        2
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        0
      type
      Withdrawal prior to initiation
    8. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        1
      3. group Id
        FG002
        num Subjects
        1
      4. group Id
        FG003
        num Subjects
        1
      type
      Physician Decision
    9. reasons
      1. group Id
        FG000
        num Subjects
        1
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Non-compliance
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        134
      2. group Id
        FG001
        num Subjects
        69
      3. group Id
        FG002
        num Subjects
        64
      4. group Id
        FG003
        num Subjects
        31
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        132
      2. group Id
        FG001
        num Subjects
        67
      3. group Id
        FG002
        num Subjects
        63
      4. group Id
        FG003
        num Subjects
        31
      type
      Initiated Treatment
    3. achievements
      1. group Id
        FG000
        num Subjects
        21
      2. group Id
        FG001
        num Subjects
        7
      3. group Id
        FG002
        num Subjects
        14
      4. group Id
        FG003
        num Subjects
        2
      type
      COMPLETED
    4. achievements
      1. group Id
        FG000
        num Subjects
        113
      2. group Id
        FG001
        num Subjects
        62
      3. group Id
        FG002
        num Subjects
        50
      4. group Id
        FG003
        num Subjects
        29
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice